Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R, Van Solingen-Ristea R, Crauwels H, Polli JW, Seal C, Yagüe Muñoz I, Thiagarajah S, Birmingham E, Spreen WR, Baugh B, van Wyk J, Vannappagari V. Patel P, et al. Among authors: spreen wr. HIV Med. 2023 May;24(5):568-579. doi: 10.1111/hiv.13439. Epub 2022 Nov 21. HIV Med. 2023. PMID: 36411596
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Han K, Gevorkyan H, Sadik Shaik J, Crauwels H, Leemereise C, Bontempo G, Win B, Chounta V, Seal C, DeMoor R, D'Amico R, Spreen WR, Ford SL. Han K, et al. Among authors: spreen wr. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0078123. doi: 10.1128/aac.00781-23. Epub 2023 Dec 1. Antimicrob Agents Chemother. 2024. PMID: 38038460 Free PMC article.
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J, Ford SL. Han K, et al. Among authors: spreen w. Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0147523. doi: 10.1128/aac.01475-23. Epub 2024 May 6. Antimicrob Agents Chemother. 2024. PMID: 38709006 Free PMC article. Clinical Trial.
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.
Mussini C, Cazanave C, Adachi E, Eu B, Alonso MM, Crofoot G, Chounta V, Kolobova I, Sutton K, Sutherland-Phillips D, Urbaityte R, Ehmann A, Scherzer J, de Los Rios P, D'Amico R, Spreen W, van Wyk J. Mussini C, et al. Among authors: spreen w. AIDS Behav. 2024 Oct 8. doi: 10.1007/s10461-024-04490-0. Online ahead of print. AIDS Behav. 2024. PMID: 39375290
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli JW, Baker M, Ford SL, Han K, Russu A, Crauwels H, D'Amico RD, Spreen WR, van Wyk J. Patel P, et al. Among authors: spreen wr. Ther Adv Infect Dis. 2023 Dec 13;10:20499361231214626. doi: 10.1177/20499361231214626. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 38107552 Free PMC article. Review.
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X, Nelson RP Jr, Emmanuel P, Wiznia A, Mitchell C, Church JA, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S. Sáez-Llorens X, et al. Among authors: spreen w. Pediatrics. 2001 Jan;107(1):E4. doi: 10.1542/peds.107.1.e4. Pediatrics. 2001. PMID: 11134468 Clinical Trial.
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Staszewski S, et al. Among authors: spreen w. JAMA. 2001 Mar 7;285(9):1155-63. doi: 10.1001/jama.285.9.1155. JAMA. 2001. PMID: 11231744 Clinical Trial.
86 results